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ABSTRACT 
 
Long non-coding RNA LUCAT1 promotes tumorigenesis by controlling 
ubiquitination and stability of DNA methyltransferase1 in esophageal squamous 
cell carcinoma 
 
Jung-ho Yoon 
Department of Medical Science 
The Graduate School, Yonsei University 
(Directed by Professor Sang Kil Lee) 
 
Esophageal squamous cell carcinoma (ESCC) is a fatal malignancy whose 
pathophysiology is not well known. Recently, a considerable number of long non-
coding RNAs (lncRNA) have been reported to be involved in various cancers. In this 
study, we validated the mechanism of LUCAT1 in ESCC. We used next-generation 
transcriptome sequencing (RNA-seq) to analyse transcriptomes using thirteen paired 
adjacent normal tissues and ESCC tissues. Among the lncRNAs, LUCAT1 was 
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significantly overexpressed in ESCC compared to adjacent normal tissues (p <0.001). 
LUCAT1 was significantly upregulated in ESCC cell lines and cancer tissue of patients 
with ESCC compared to normal cells and adjacent normal tissue, respectively (p 
<0.001). The expression of LUCAT1 in normal tissues adjacent to cancer of ESCC 
patients was significantly high compared to that in the tissue of normal patients (p 
<0.001). LUCAT1 blocked the apoptosis and induced the migration and invasion of 
KYSE-30 cell lines and HCE-4 cell lines. LUCAT1 siRNAs up-regulated the tumor 
suppressor genes, including GADD45G, GAS1, HPGD, and SFRP2 by reducing the 
methylation of these genes. LUCAT1 siRNAs reduced the protein level of DNA 
methyltransferase 1 (DNMT1) without interfering with transcription. LUCAT1 
controlled the ubiquitination and degradation of DNMT1 in an E3 ubiquitin-protein 
ligase UHRF1-dependent manner. Patients with high LUCAT1 had a significantly 
lower survival rate than patients with low LUCAT1. In conclusion, our results suggest 
that the lncRNA LUCAT1 regulates the stability of DNMT1 and inhibits the expression 
of tumor suppressors through DNA methylation, leading to the proliferation and 
metastasis of ESCC. We found that LUCAT1 could be a drug and biomarker target for 
ESCC in this study.  
 
 
Key words: long non-coding RNA, LUCAT1, DNA methyltransferase 1, 
   esophageal squamous cell carcinoma   
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Ⅰ. INTRODUCTION 
 
 
Esophageal cancer is the eighth most common cancer and the sixth leading cause of 
cancer related mortality.
1
  The two main types of esophageal cancer are squamous cell 
carcinoma (ESCC) and adenocarcinoma. ESCC is linked to heavy smoking and alcohol 
consumption.
2
 Despite recent advances in clinical practice, the prognosis of ESCC 
patients is poor, as until now, there have not been any targets for drug development in 
the major pathways involved in the development of ESCC. Therefore, it is urgent to 
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research new key routes to ESCC and find targets to treat ESCC. 
Recently, studies using ESCC cells and clinical tissues have shown that the 
suppression of tumor suppressor expression by DNA methylation is important for the 
early development and progression of esophageal cancer.
3
 However, the detailed 
mechanisms leading to ESCC have yet to be fully elucidated, and it is important to 
develop new potential biomarkers for early diagnosis and new treatments. 
Long non-coding RNAs (lncRNAs) are functionally defined as transcripts >200 nt in 
length with no protein-coding potential, and many are noted for their role in controlling 
the major factors driving carcinogenesis in various cancers.
4
 Although the mechanisms 
of lncRNAs have not been well documented, they can be separated based on their 
influence on chromatin state and methylation, the stability of proteins and complexes, 
or by acting as a sponge for miRNA inhibition.
5
 LncRNA has recently been noted for 
its role in controlling many of the major factors driving the post-transcriptional and 
epigenetic mechanisms. Many cancer studies are underway, but the function of 
lncRNA in esophageal cancer is not well known. Recently, the interactions between 
lncRNA and DNA methylation have been considered important for cancer biology. 
6
 
Epigenetic changes caused by DNA methylation are important for the onset and 
progression of cancer.
7
 Promoter methylation of the tumor suppressor results in 
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transcriptional silencing and loss of gene function.
8
 DNA methylation is performed by 
three DNA methyltransferases: DNMT1, DNMT3a, and DNMT3b.
9
 DNMT1 is 
primarily involved in methylation maintenance, and hemisomylated cytosines can be 
methylated on double-stranded DNA molecules, which may be involved in the 
methylation of the strand.
9
 However, DNMT3a and DNMT3b play an important role in 
de novo methylation. Methylation can be performed on unmethylated double-stranded 
DNA. DNA methylation is generally associated with gene suppression, and DNA 
demethylation is usually associated with gene activation. The control of DNA 
methylation by lncRNA can be an important mechanism in the development and 
regulation of gene expression in disease. Recently, the relevance of lncRNAs to 
proliferative factors has been widely reported.
10-12
 
Next-generation transcriptome sequencing (RNA-seq) provides a way to describe all 
sets of transcription errors in diseases, including lncRNAs and protein-coding genes. 
Using RNA-seq to analyze various cancer tissues, functional lncRNAs in various 
cancers have recently been defined.
13-16
 However, functional lncRNAs in ESCC have 
yet to be identified. Here, we perform RNA-seq to investigate the expression levels of 
lncRNAs in 13 paired ESCC tissues. 
The LncRNA LUCAT1 was first reported to be involved in lung cancer caused by 
smoking.
17
 It is well known that smoking is the most potent cause of ESCC, so it can 
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be assumed that LUCAT1 may be involved in the carcinogenesis of ESCC. In this study, 
we investigate the role of LUCAT1 in the proliferation and invasion of ESCC and find 
that LUCAT1 plays an important role in the progression of ESCC and that the 
expression of LUCAT1 is a predictor of survival. We show that LUCAT1 interacts with 
DNMT1. In addition, we find that DNMT1 stability, which can regulate DNA 
methylation, is associated with LUCAT1 expression levels. Thus, LUCAT1 plays an 
important role in the survival and proliferation of ESCC. 
 
Ⅱ. MATERIALS AND METHODS 
 
1. Cell lines and cell culture 
KYSE-30 ESCC cells were cultured in RPMI 1640 medium (Thermo Scientific, 
Rockford, IL, USA) supplemented with Ham's F12 medium, 10% fetal bovine serum 
(FBS; Thermo Scientific), and 1% penicillin/streptomycin (Thermo Scientific). TE-2, 
HCE-4, and HCE-7 cells were cultured in Dulbecco’s modified Eagle’s medium 
(Thermo Scientific) supplemented with 10% FBS and 1% penicillin/streptomycin. 
HET-1a immortalized normal esophageal cells were cultured in BEGM medium 
supplemented with a BEGM Bullet Kit (Lonza, Walkersville, MD, USA). The growth 
medium was also supplemented with 10% FBA and 1% penicillin/streptomycin. All 
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cells were incubated in a humidified atmosphere with 5% CO2 at 37°C. TE-2, TE-3, 
HCE-4, and HCE-7 cells were kindly provided by Dr. KH Kim (Yonsei University 
Medical School, Seoul, Korea), and the other cell lines were obtained from American 
Type Culture Collection (ATCC, Rockville, MD, USA). 
 
2. ESCC patients and tissue sampling 
Thirty-eight patients with ESCC were enrolled for this study. The clinicopathologic 
findings and tissue were collected prospectively and summarized in Table 1. All study 
participants provided informed consent, and the study design was approved by the 
Public Institutional Bioethics Committee designated by the Ministry of Health and 
Welfare (South Korea) (No. 4-2014-0775). Tissue samples were collected by 
endoscopic biopsy from cancer and adjacent normal appearing mucosa. The normal 
tissues from normal patients were obtained from another clinical study on non-erosive 
reflux disease. The collected tissues were immediately transferred to RNAlater solution 
(Ambion), delivered to the laboratory, and then stored in a deep refrigerator until 
analysis. 
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Table 1.Clinicopathologic characteristics of enrolled patients 
Characteristics N = 38 
*Age, yr (range) 68 (52 - 91) 
Sex   
Male 31 (82%) 
Female   7 (18%) 
Stage   
I 6 (16%) 
II 6 (16%) 
III 21 (55%) 
IV 5 (13%) 
Differentiation 
ESCC, WD 3 (8%) 
ESCC, MD 26 (68%) 
ESCC, PD 2 (5%) 
ESCC, uncertain 7 (19%) 
Initial treatment 
 
Surgery 11 (29%) 
Chemoradiotherapy 16 (42%) 
Chemotherapy only 2 (5%) 
Radiotherapy only 1 (3%) 
None 8 (21%) 
* Data represented as median value 
ESCC, esophageal squamous cell carcinoma; WD, well differentiated; MD, moderately 
differentiated; PD, poorly differentiated 
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3. Total RNA extraction, reverse transcription and quantitative real-time PCR 
Total RNA extraction from ESCC cells and tissues was performed using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA). RNA was quantified using a Nanodrop (ND-
100; Nanodrop Technologies lnc., Wilmington, DE, USA), and purity was determined 
based on the 260/280 nm ratio and by analysis on 1% agarose gels. cDNA synthesis 
was performed using 2.0 μg of total RNA with Superscript II (Invitrogen). The relative 
expression of LUCAT1 was determined and analyzed by quantitative real-time PCR 
using a Light Cycler 480 Real-Time PCR machine and iQ SYBR Green Supermix 
(Applied Biosystems Inc., Carlsbad, CA, USA). The Ct value of the sample was 
normalized to the U6 or GAPDH expression, and the 2-ΔΔCt value was calculated. 
Primers used for qRT-PCR are shown in Table 2. 
 
Table 2. Primer sequences for qRT-PCR    
Gene Direction Sequence (5' to 3') 
   
LUCAT1 Forward 5'- GCTCGGATTGCCTTAGACAG -3' 
  Reverse 5'- GGGTGAGCTTCTTGTGAGGA -3' 
   
MEG3 Forward 5'- CAGCCAAGCTTCTTGAAAGG -3' 
  Reverse 5'- TTCCACGGAGTAGAGCGAGT -3' 
   
ZFPM-AS1 Forward 5'- AAGAGGTCAGGAGGCACCTT -3' 
  Reverse 5'- AGGCAGGAGAATTGCTTGAA -3' 
   
RP5-1112F19.2 Forward 5'- GTGAAACCCCGTCTCTACCA -3' 
  Reverse 5'- CAAGCAATTCTCCTGCCTTC -3' 
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DNMT1 Forward 5'- ACGACCCTGACCTCAAATAT -3' 
  Reverse 5'- CCATTAACACCACCTTCAAGA -3' 
   
GADD45G Forward 5'-GGTGAGTACAGTCCCGTCC-3' 
  Reverse 5'-GCAAAACAGGCTGAGCTTCT-3' 
   
SFRP2 Forward 5'-AGTGGTGTTTGGTGGAGGAG-3' 
  Reverse 5'-TGCATCCTGGTTTTCCTTTC-3' 
   
GAS1 Forward 5'-GAAACTCCCAACTCGTCTGC-3' 
  Reverse 5'-ACCTTCCCTTTCGAGTCCAG-3' 
   
HPGD Forward 5'-TAGCCATTCTGATCGCTGTG-3' 
  Reverse 5'-AGACACATGGCCAACAAACA-3' 
   
U6 Forward 5'-CTCGCTTCGGCAGCACA-3' 
 
  Reverse 5'-AACGCTTCAGGAATTTGCGT-3' 
   
GAPDH Forward 5'-CCGGGAAACTGTGGCGTGATGG-3' 
  Reverse 5'-AGGTGGAGGAGTGGGTGTCGCTGTT-3' 
   
 
 
 
4. Small interfering RNA (siRNA) transfection 
For transfection, all cells are counted in 6 wells (3X10
5
) and incubated in a 37 ° C 
incubator. After 24 hours, siRNA LUCAT1 and RNAi negative control (siCT; 
Invitrogen, Carlsbad, Calif., USA) were transfected according to the protocol of 
Lipofectamine 2000 using Lipofectamine 2000 reagent (Invitrogen). The sequences of 
target siRNAs for LUCAT1 are listed in Table 3. 
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Table 3. siRNAs targeting lncRNA LUCAT1 
Gene Direction Sequence (5' to 3') 
Si LUCAT1_1 Sense 5'- CAG AAG AUG UCA GAA GAU AAG GAU U-3' 
  Antisense 5'-A AUC CUU AUC UUC UGA CAU CUU CUG-3' 
Si LUCAT1_2 Sense 5'-GCACAGAUAAAUUUCUCUUACUGUA-3' 
  Antisense 5'-UACAGUAAGAGAAAUUUAUCUGUGC-3' 
 
 
5. LUCAT1 overexpression plasmid construction 
LUCAT1 cDNA was amplified using a PCR system (Roche Applied Science). To 
insert the cDNA into the pcDNA3.1 (+) expression vector, LUCAT1_NHel_F 
(acccaagctggctagc CAATGCCCAGACCTCCAG) and LUCAT1_Xbal_R 
(aaacgggccctctaga TTGACTGCAAGAGCTTGAAG) were used as cloning primers. 
The pcDNA3.1 (+) expression vector was purchased from Addgene. KYSE-30 cells 
were transfected with 1 μg of pcDNA3.1-LUCAT1 for 24 h using Lipofectamine 2000 
(Invitrogen). 
6. Cell proliferation analysis 
MTS assays (Promega, Madison, WI, USA) were used to measure cell proliferation 
in 96-well plates. Plates were incubated in a dark room for 1 h, and enzyme-linked 
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immunosorbent assays (ELISAs) were performed. Briefly, ESCC cells were transfected 
with 50 nM siLUCAT1 or siCT, and cell proliferation was measured from 0 to 72 h. 
For rescue experiments, cells were transfected with pcDNA-LUCAT1 48 h after siRNA 
transfection, and cell proliferation was assessed.  
 
7. Apoptosis analysis  
KYSE-30 cells were transfected with LUCAT1 siRNA or siCT, and the cell pellet 
was recovered after 48 h. The cell pellet was resuspended in 1× binding buffer (BD 
Bioscience, San Jose, CA, USA) and phosphate-buffered saline (PBS). Cells were 
stained with propidium iodide and fluorescein isothiocyanate (FITC) annexin V using a 
FITC-Annexin V kit (BD Bioscience). For analysis by flow cytometry using a 
FACSverse instrument (BD Biosciences), stained cells were incubated at for 15 min. 
Data were analyzed using Flow Jo software (Treestar, Ashland, OR, USA). Three 
experiments were conducted for each assay. 
8. Invasion assay and Migration assay 
To perform the invasion assay, two siLUCAT1s were transfected into KYSE-30 cells, 
and the cells were then reseeded in Matrigel Invasion Chambers (BD Biosciences) in a 
24-well culture plate. The bottom chamber was filled with medium containing 10% 
FBS. After 24 h, the non-invading cells were removed from the insertion chamber 
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using a cotton swab. The lower side of the upper chamber was fixed and stained with 
Diff-Quik stain (Dade Behring Inc., Newark, DE, USA). Invading cells were visualized 
using a virtual microscope (BX51; Olympus, Tokyo, Japan) in five random fields, 
counted, and averaged. 
For migration analysis, KYSE-30 cells (2 × 10
5
) were transfected with siLUCAT1s 
and siCT. The cells were grown for 24 h, and a wound was then generated using a P200 
pipette tip. A virtual microscope (BX51; Olympus) was used to measure the wound 
width at 0 and 24 h. Image analysis was performed using Image J software (NIH). The 
experiment was performed three times. 
 
9. Western blot 
Whole lysates were used with 1× RIPA buffer (Cell Signaling Technology, Danvers, 
MA, USA) containing protease inhibitor (GenDEPOT, Barker, TX, USA). Protein was 
separated using sodium dodecyl sulfate-polyacrylamide gels and transferred to 
polyvinylidene fluoride membranes (Millipore, Darmstadt, Germany). After blocking 
for 30 min at room temperature with 3% bovine serum albumin (Thermo Scientific), 
the membranes were incubated with primary antibodies, followed by incubation with 
horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit secondary 
antibodies (GenDEPOT). For western blot analysis, the following antibodies were used: 
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anti-mono- and polyubiquitinylated monoclonal antibodies (Enzo, USA), anti-DNA 
methyltransferase 1 (DNMT1 Abcam, USA), anti-zinc finger E-box binding homeobox 
1 (ZEB1 Cell Signaling Technology), anti-E-cadherin (BD Biosciences), anti-N-
cadherin (BD Biosciences), anti-Bcl-2 (Cell Signaling Technology), anti-Bcl-xl (Cell 
Signaling Technology), anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
and anti-β-actin (Thermo Scientific). The membranes were then reacted with ECL 
solution (GenDEPOT) and exposed to an X-ray film processor (CP1000; AGFA, 
Greenville, SC, USA) or an Image Quant LAS 4000 (GE Healthcare, Piscataway, NJ, 
USA). 
 
10. RNA immunoprecipitation (RIP) 
For immunoprecipitation of endogenous RNA-protein complexes, cells were lysed 
with IP buffer (Thermo Fisher Scientific, USA) and resuspended in RIP buffer (Abcam) 
with RNase inhibitor (GenDEPOT) and protease inhibitor (GenDEPOT). For shearing 
of chromatin, we used 20 cycles of shearing under cooling conditions, with 15s on and 
30s off for each cycle (170–190 W) and water bath sonication. After sonication, the 
antibodies were added to the supernatant obtained by centrifugation and then incubated 
overnight at 4°C with a rotator. After incubation, 20 μL of Magna Chip protein 
magnetic beads (Millipore) was added, and samples were reacted on a rotator at 4°C 
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for 1 h. After washing twice with RIP buffer, samples were dissolved with TRIzol 
reagent or RIPA. 
11. Methylation specific PCR (MS-PCR) 
Genomic DNA was extracted from cells using the DNeasy Blood & Tissue kit 
(Qiagen, Valencia, CA, USA). DNA bisulfate conversion was performed with the EZ 
DNA Methylation-Gold Kit™ (Zymo Research, Irvine, CA, USA) followed by MS-
PCR. The MS-PCR primers used for target genes are shown in Table 4. 
 
Table 4. Primer sequences for MS-PCR 
   
Gene Direction Sequence (5' to 3') 
   
GADD45G Forward 5'- TTTAGGAAGGTTTAGGTTAGGACGT -3' 
Methylation Reverse 5'- GTTTTAAAAAAACAACGCAATCG -3' 
   
GADD45G Forward 5'- AGTAGTAGTAGTAAGATGGAGGCGA -3' 
Unmethylation Reverse 5'- ATTTTAAAAAAACAACACAATCAAC -3' 
   
GAS1 Forward 5'- AAGAGGTCAGGAGGCACCTT -3' 
Methylation Reverse 5'- AAAACCTACCCTATAAACCTAAACG -3' 
   
GAS1 Forward 5'- AGTAGTAGTAGTAAGATGGAGGTGA -3' 
Unmethylation Reverse 5'-AACCTACCCTATAAACCTAAACACA -3' 
SFRP2_1 Forward 5'- GTTTGTCGGAGTTATTAGGATGTC -3' 
Methylation Reverse 5'- CTAATAATCACCTCGATAAAACGAT -3' 
   
SFRP2_1 Forward 5'-TTGTTGGAGTTATTAGGATGTTGG-3' 
Unmethylation Reverse 5'-CTAATAATCACCTCAATAAAACAAT-3' 
   
SFRP2_2 Forward 5'-GGAAACGGTCGTATTTAAGTATGTC-3' 
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Methylation Reverse 5'-CACCAAAAAATTCCTATACTCGCT-3' 
   
SFRP2_2 Forward 5'-GGGAAATGGTTGTATTTAAGTATGTT-3' 
Unmethylation Reverse 5'-ACACCAAAAAATTCCTATACTCACT-3' 
   
HPGD Forward 5'-GATTTTTTATAATTGTTTTTTTCGT-3' 
Methylation Reverse 5'-ACCATCCATAAAACTTTTACACG-3' 
   
HPGD Forward 5'-ATTTTTTATAATTGTTTTTTTTGT-3' 
Unmethylation Reverse 5'-CAACCATCCATAAAACTTTTACACAC-3' 
   
 
 
12. RNA-sequencing followed by next-generation sequencing (NGS) 
RNA from 13 paired adjacent normal tissues and ESCC tissues was extracted using 
TRIZOL reagent (Invitrogen) for RNA extraction. Illumina Truseq stranded and 
unstranded mRNA library prep kits (Illumina, USA) were used for deep sequencing 
library preparation according to the manufacturer’s protocol. Libraries were sequenced 
in paired-end format to a length of 101 bp using the HiSeq 2000 platform (Macrogen 
Corporation, Republic of Korea). 
13. Expression profiling 
All RNA-seq data ENCODE, TCGA, and GTExRPDs were used to quantify gene 
expression values based on annotations using feature Counts version 1.5.1 with 
parameters -t exon -g gene_id –min Overlap “average length of reads divided by 2” -s 
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2. The -T option was specified only for paired-end reads with -p -B -C. 
 
14. Statistical analysis 
All data were analyzed for continuous and categorical variables and presented as 
means ± standard error of the mean (SEM). Statistical tests included the t-test, χ2 test, 
and Fisher’s exact test. The degree of expression of LUCAT1 in ESCC was categorized 
as low or high based on the median of LUCAT1 expression. Continuous variables were 
presented as means ± standard deviation. Categorical variables were presented as 
numbers with percentages. Descriptive statistics were used to characterize the baseline 
clinicopathologic characteristics of patients. Survival curves were estimated according 
to the Kaplan–Meier method, and the differences according to LUCAT1 expression 
were examined using the log-rank test. Additionally, Fisher’s exact test, Student’s t-test, 
and the Mann–Whitney U test were used to compare LUCAT1 expression with the 
clinical T stage, N stage, M stage, and overall stage of the ESCC patients. However, 
there was no statistically significant difference (data not shown). A value of p < 0.05 
was considered statistically significant. All statistical procedures were conducted using 
the statistical software SPSS for Windows (version 18.0; SPSS Inc., Chicago, IL, USA). 
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Ⅲ. RESULTS 
 
1. ESCC related lncRNA expression analysis from RNA-seq data 
To determine the expression of lncRNAs in esophageal carcinoma, RNA-seq was 
performed using RNA of three pairs of esophageal cancer patients (Fig. 1a). As a result, 
we selected four annotated lncRNAs that were highly expressed in cancer tissues 
compared with adjacent tissues (Table 5). Among lncRNAs, ZFPM2-AS1, MEG3, RP5-
1112F19.2, and LUCAT1 were significantly overexpressed in ESCC compared to 
adjacent normal tissues (p<0.001) (Fig. 1b). LUCAT1 was located at chr5:90597115-
90610219 (Fig. 1c). In addition, RNA-seq analysis of 10 patients with esophageal 
cancer was performed. In these RNA-seq results, the adjusted p-value of LUCAT1 was 
not valid. However, the RNA-seq results of all 13 patient RNAs showed valid values 
(Table 6). The RNA-seq analysis of all 13 patients with esophageal cancer confirmed 
the expression of LUCAT1 in esophageal cancer. Previous reports on the RNA-seq 
data
18
 and TCGA data of 15 Chinese patients with esophageal cancer also showed that 
LUCAT1 expression was greater in cancer. LUCAT1 was more highly expressed in 
cancer compared to normal tissue samples (GTEx normal 338 non-paired samples) 
with ESCC (TCGA tumor 95 non-paired samples) and ESAD (TCGA tumor 89 non-
paired samples) in TCGA data. In addition, in HNSC (43 paired samples), LUSC (51 
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paired samples), and LUAD (58 paired samples), LUCAT1 was also more highly 
expressed than in normal samples in TCGA data (Fig. 2). 
 
 
 
Table 5. Highly expressed lncRNAs       
gene_id locus fold Change 
log2_fold 
Change 
p-value 
adjusted  
p-value 
ZFPM2-
AS1 chr8:106791753-
107072752 
288.783352 8.173843765 1.36E-08 0.0001133 
(lncRNA) 
MEG3 chr14:101245746-
101327354 
23.3410585 4.544798083 0.000055 0.0758876 
(lncRNA) 
RP5-
1112F19.2 chr20:50448335-
50479451 
9.73462487 3.283125386 4.05E-05 0.0758876 
(lncRNA) 
LUCAT1 chr5:90598115-
90610219 
16.1155246 4.010379249 0.00028 0.211573 
(lncRNA) 
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Figure 1. Genome wide analysis of lncRNA expression by RNA-seq. Schematic 
representation of RNA-seq analysis workflow (a). LncRNA levels were measured by 
SYBR qRT-PCR and calculated by 2-ΔΔCT (* p ≤ 0.05; ** p ≤ 0.01). Expression of 
LUCAT1 was higher than that of RP5-1112F19.2, ZFPM-AS1, and MEG3 in the ESCC 
tissues than in the adjacent normal mucosa (n=15) (b). Location of lncRNA LUCAT1 
and RNA-seq data reads were visualized using University of California, Santa Cruz 
(UCSC) Genome Browser (c). 
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Table 6. Highly expressed LUCAT1         
Gene_id  Locus  
Fold Log2_fold 
p-value  
Adjusted  
Change  Change  p-value  
LUCAT1 chr5:          
90598115-
90610219  
11.8702 3.5692 6.00E-15 1.30E-13 
(lncRNA)  
 
 
 
Figure 2.  Expression of LUCAT1 in RNA-seq data and TCGA data. The first bar 
(Sev) shows the expression level of LUCAT1 in the RNA-seq data (13 paired samples), 
and the next bar (Li) shows the expression level of LUCAT1 using RNA-seq data (15 
paired samples) reported in China.
18
 The expression level of LUCAT1 was also 
expressed using TCGA data. In order, the p-values are 0.0007324, 0.0004272, 2.2e-16, 
1.043e-13, 4.101-e05, 0.01794, and 2.713e-08. 
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2. LUCAT1 is highly overexpressed in ESCC cell lines and cancer tissues 
LUCAT1 was significantly elevated in the five ESCC cell lines compared to normal 
esophageal HET-1A cells (Fig. 3a). The expression of LUCAT1 in cancer tissues and 
adjacent normal tissues from 38 patients with ESCC and 20 normal tissues from 
normal patients was measured by qRT-PCR. The expression of LUCAT1 was 
significantly higher in cancer tissues compared with adjacent normal tissues of patients 
with ESCC (p <0.001) (Fig. 3b). The mean Ct value of LUCAT1 was about 14 times 
higher in cancer tissues than in adjacent normal tissues. The levels of LUCAT1 of 
normal tissues of 20 normal patients were significantly lower than those of adjacent 
normal tissues of patients with ESCC (p<0.001). Furthermore, the Ct value of LUCAT1 
was about 318 times higher in adjacent normal tissues compared to normal tissues of 
normal patients. According to this finding, LUCAT1 might play a role in the early 
stages of ESCC carcinogenesis. The incensement of LUCAT1 in patients with ESCC 
was also confirmed in the TCGA database (Fig. 2). 
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Figure 3. LUCAT1 is overexpressed in ESCC cells and tissues. LUCAT1 expression 
was increased in esophageal cancer cells KYSE-30, HCE-4, HCE-7, TE-2, and TE-3 
compared to Het-1A, a normal esophageal cell (a). The expression of LUCAT1 was 
higher in the ESCC tissues than in the adjacent normal mucosa (n=38). The level of 
LUCAT1 in the adjacent normal mucosa of ESCC patients was significantly higher 
than that in the normal mucosa of the normal controls (n=20) (b). The level of LUCAT1 
was measured by SYBR qRT-PCR and calculated by 2-ΔΔCT (* p ≤ 0.05; ** p ≤ 0.01). 
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3. The expression of LUCAT1 is correlated with prognoses of ESCC patients  
Patients’ clinicopathologic features were summarized in Table 1. The mean age of 
the patients included in the study was 68 years old, and men accounted for 81%. To 
analyze the effect of LUCAT1 on the survival of ESCC, patients were categorized in 
terms of LUCAT1 expression into a low group and a high group, which were 
determined using median values for the 24 patients whose data were available. Patients 
in the high group had poor survival compared to patients in the low group over an 
examination period of 15 months (range 1–36) (Fig. 4). 
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Figure 4. Overall survival among patients according to LUCAT1 expression. 
Kaplan–Meier estimates of overall survival among patients in the high and low 
LUCAT1 expression groups. The mean survival of high LUCAT1 expression-group 
patients was 19 months, while it was 27 months for low LUCAT1 expression-group 
patients. 
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4. Level of expression of LUCAT1 determines proliferation of ESCC cells and 
induces apoptosis 
After confirming the increased expression of LUCAT1 in ESCC, two different 
siRNAs and overexpression vectors were constructed to confirm its function. Both 
siRNAs (siLUCAT1_1 and siLUCAT1_2) reduced the expression of the target lncRNA, 
LUCAT1, as much as 50% compared to scrambled siRNA (siCT) (Fig. 5a). The ectopic 
expression of LUCAT1 by the transfection of pcDNA-LUCAT1 was confirmed by 
qRT-PCR (Fig. 5b). 
Cell proliferation assays revealed that cell proliferation significantly decreased after 
two different siLUCAT1s treatments in four different ESCC cell lines compared to 
control and siCT-treated cells. Cell proliferation, in pcDNA-LUCAT1 treatment after 
siLUCAT1s, was restored in comparison to siLUCAT1s treatment with statistical 
significance (Fig. 6). The effects of siLUCAT1s were significant in all the cell lines; 
however, the magnitude of the difference was larger in the KYSE-30 cell line. For this 
reason, the KYSE-30 cell line was used to ensure the most functional study. 
To follow up on our cell proliferation results, we examined the effect of LUCAT1 on 
apoptosis. When KYSE-30 cells and HCE-4 cells were treated with two different 
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siLUCAT1s, the induction of apoptosis was confirmed by flow cytometry using 
PI/Annexin V staining (Fig. 7a). Apoptosis was increased 2 to 2.5 times in the 
siLUCAT1s-treated cells compared to the control group (Fig. 7b). To determine the 
quantitative relationship, caspase 3/7 protein was measured by the ELISA method, and 
it was found that siLUCAT1s significantly increased caspase 3/7 activity by 1.5 and 2 
times, respectively (Fig. 7c). siLUCAT1s induced the cleavage of Poly (ADP-ribose) 
polymerase and caspase 9 (Fig. 7d). siLUCAT1s not only induced p53 and Bax but 
also reduced Bcl-2 and Bcl-XL (Fig. 7d). All these changes induced by siLUCAT1s 
were rescued by the ectopic expression of LUCAT1 caused by the transfection of 
pcDNA-LUCAT1.  
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Figure 5. Generation of loss of function LUCAT1 using siRNA and gain of 
function LUCAT1 using overexpression vector in ESCC cells. LUCAT1 expression 
was detected by qRT-PCR in KYSE-30 cells and HCE-4 cells transfected with (a) 
siRNAs and (b) pcDNA-LUCAT1. Data are the means of three independent 
experiments ± SEM. The asterisk represents a statistically significant difference 
compared with the scrambled control (* p ≤ 0.05; ** p ≤ 0.01). 
 
 29 
 
 
Figure 6. Inhibition of LUCAT1 expression inhibits cell proliferation of ESCC 
cells. KYSE-30 cells and HCE-4 cells were transfected with siLUCAT1s or pcDNA-
LUCAT1, and the expression of LUCAT1 was detected using qRT-PCR. Cell 
proliferation was measured by MTS assay. The data were obtained from three 
independent experiments. The displayed data represent the mean values ± SEM. 
Asterisks represent statistically significant differences when compared to pcDNA or 
siCT (* p ≤ 0.05; ** p ≤ 0.01). 
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Figure 7. Inhibition of LUCAT1 expression induces apoptosis of ESCC cells. 
Apoptosis was measured by flow cytometry using PI/Annexin V staining (a). Early and 
late apoptosis combined (b). Apoptotic ratios were increased in siLUCAT1s. Caspase 
Glo3,7 assay was performed on KYSE-30 cells. Luminescence activity was measured 
using a Luminescence Microplate Reader (c). Apoptosis markers associated with 
LUCAT1 expression were confirmed by immunoblot analysis on KYSE-30 cells and 
HCE-4 cells (d). The data were obtained from three independent experiments. The 
displayed data represent the mean values ± SEM. Asterisks represent statistically 
significant differences when compared to siCT (* p ≤ 0.05; ** p ≤ 0.01). 
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5. Inhibition of LUCAT1 expression inhibits invasion and migration of ESCC 
cells 
To investigate whether LUCAT1 is involved in the invasion and migration of ESCC, 
two siLUCAT1s were transfected to the KYSE-30 cells and HCE-4 cells replated onto 
24 wells. Wound closure was significantly suppressed in siLUCAT1s compared to siCT 
(Fig. 8a). Two siRNAs for LUCAT1 also significantly reduced the invasion of KYSE-
30 cells and HCE-4 cells (Fig.8b). All the effects of siRNAs for LUCAT1 were reduced 
by the transfection of pcDNA-LUCAT1 (Fig. 8a, b).  
Two different siLUCAT1s increased the expression of the epithelial marker E-
cadherin. On the other hand, the expression of the mesenchymal markers N-cadherin, 
Snail, and ZEB1 was reduced. These changes of proteins were restored by the 
overexpression of LUCAT1 (Fig. 8c). These experimental results show that LUCAT1, 
which is a typical phenotype of cancer, is involved in invasion and migration. 
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Figure 8. Inhibition of LUCAT1 by siRNA inhibits migration and invasion of 
ESCC cells. The wound healing assay (a) and invasion assay (b) were performed by 
transfection of siCT and siLUCAT1s in KYSE-30 cells and HCE-4 cells. In the same 
way, EMT markers were also confirmed by immunoblot (c). Data were obtained from 
three independent experiments. The displayed data represent the mean values ± SEM. 
The asterisk indicates a statistically significant difference compared to siCT (* p ≤ 0.05; 
** p ≤ 0.01). 
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6. LUCAT1 regulates ESCC-related genes 
To investigate the mechanisms involved in the development and invasion of ESCC, 
a microarray of cancer-related genes was adopted after treatment of siLUCAT1s. The 
expression of 770 cancer-related genes was analyzed (Fig. 9a, b). We found that the 
expression levels of tumor suppressor genes were affected by siRNAs for LUCAT1 
(https://bioinfo.uth.edu/TSGene/index.html). qRT-PCR confirmed the findings of the 
microarray, and the mRNA levels of these tumor suppressor genes were significantly 
reduced by siLUCAT1 compared to the control. Interestingly, we found that the 
activities of these selected genes were regulated by methylation (Fig. 9c). Next, we 
performed MS-PCR after the transfection of siRNAs and found that siLUCAT1s 
reduced the methylation of GADD45G, GAS1, SFRP2, and HPGD. We found that 
siRNAs affected not only methylation status but also the activity of genes at the same 
time (Fig. 10a-d), confirming that LUCAT1 is involved in the methylation of a series of 
genes. To determine whether LUCAT1 is involved in the methylation of the tumor 
suppressor genes involved in histone modification, we observed changes in H3K4me3, 
H3K9me3, H3K27me3, and H3K36me3 depending on the expression of LUCAT1 (Fig. 
10e). However, we did not find significant changes in these genes after siLUCAT1 
treatment. 
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Figure 9. Cancer-related target gene expression in LUCAT1 silencing. Heatmap of 
differentially expressed genes between siLUCAT1 and siCT in KYSE-30 cells (a). 
Volcano plot of cancer-related gene expression levels by siLUCAT1. Points to the right 
represent candidates that were upregulated, while points to the left represent candidates 
that were downregulated (b). Selection of potential target genes based on data analysis 
(c).  
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Figure 10. GADD45G, GAS1, SFRP2 and HPGD are regulated by LUCAT1 
expression. Expression levels of GADD45G (a), GAS1 (b), SFRP2 (c) and HPGD (d) 
were confirmed by qRT-PCR using siCT or siLUCAT1 transfected into KYSE-30 cells 
and MS-PCR, respectively. The data were obtained from three independent 
experiments. The displayed data represent the mean values ± SEM. The asterisk 
indicates a statistically significant difference compared to siCT (* p ≤ 0.05; ** p ≤ 
0.01). The KYSE-30 cells were transfected with siRNA targeting LUCAT1 and 
subjected to immunoblots using H3K4me3, H3K9me3, H3K27me3, and H3K36me3 
antibodies to measure histone levels. H3 was used as a loading control (c). 
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7. LUCAT1 regulates ubiquitination of DNMT1 by relying on UHRF1 
We determined the effect of LUCAT1 on DNMT1, which is responsible for 
maintenance DNA methylation and aberrant methylation patterns associated with 
certain human tumors and developmental abnormalities.
19
 The siRNAs for LUCAT1s 
reduced the protein level of DNMT1 compared to siCT in KYSE-30 cells (Fig. 11a) 
but not mRNA (Fig. 11b). KYSE-30 cells were treated with cycloheximide after the 
knockdown of LUCAT1. The incubation of cells with cycloheximide did not affect the 
decrease of DNMT1 protein levels caused by siRNAs for LUCAT1 (Fig. 11c). We also 
found that proteasome inhibitor MG132 almost completely inhibited the decrease of 
the DNMT1 protein levels caused by siRNAs for LUCAT1 (Fig. 11d). Regarding this 
finding, we speculated that LUCAT1 enhanced the expression of DNMT1 not at the 
transcriptional level but at the posttranscriptional level (e.g., methylation, 
phosphorylation, acetylation, and ubiquitination). 
Next, we performed RIP using DNMT1 antibody and found that LUCAT1 binds to 
DNMT1 (Fig. 12a). To investigate how LUCAT1 regulates the stability of DNMT1, 
immunoprecipitation with DNMT1 antibody was performed after treatment with 
MG132 and siLUCAT1s. The ubiquitination of DNMT1 was confirmed by 
ubiquitination antibody at the same time. The results indicated that the ubiquitination 
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of DNMT1 was more exaggerated by siLUCAT1s compared to the control (Fig. 13a). 
The ectopic expression of LUCAT1 restored the reduction of DNMT1 proteins and 
DNMT1 ubiquitination induced by siRNAs. The exact mechanism of the ubiquitination 
of DNMT1 remains unclear, but it has been reported that the overexpression of 
ubiquitin-like-containing PHD and RING finger domains protein 1 (UHRF1) causes 
the ubiquitination of DNMT1.
20
 To establish the relationship between LUCAT1 and 
UHRF1, we introduced siRNA and an expression vector for UHRF1. The 
overexpression of UHRF1 alone induced the ubiquitination of DNMT1 to a similar 
extent observed in the knockdown of LUCAT1 (Fig. 13b). The knockdown of UHRF1 
absolutely blocked the DNMT1 ubiquitination that was induced by the siRNAs of 
LUCAT1. Thus, our results indicate that LUCAT1 induces DNMT1 ubiquitination, 
which is determined by the presence of UHRF1. 
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Figure 11. LUCAT1 regulates the stability of DNMT1. KYSE-30 cells were 
transfected with siCT or siLUCAT1s and immunoblotted with DNMT1 antibody to 
confirm the expression of DNMT1 (a). RT-PCR analysis of DNMT1 expression in 
KYSE-30 cells transfected with siLUCAT1s (b). The expression of DNMT1 was 
confirmed by immunoblotting KYSE-30 cells treated with cycloheximide (100 μg/ml) 
(c). KYSE-30 cells transfected with siLUCAT1s were cultured in the presence or 
absence of MG132 and then underwent immunoblotting analysis with anti-DNMT1 (d).  
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Figure 12. LUCAT1 binding DNMT1. KYSE-30 cell lysate was immunoprecipitated 
with DNMT1 antibody and subjected to RIP assay to detect the binding of LUCAT1 
and DNMT1 by qRT-PCR (a). After nuclear and cytosolic separation, RNA was 
extracted from the nuclear and cytoplasmic fractions of KYSE-30 cells, and LUCAT1 
expression was measured by qRT-PCR (b). The data were obtained from three 
independent experiments. The displayed data represent the mean values ± SEM. The 
asterisk indicates a statistically significant difference compared to siCT (* p ≤ 0.05; ** 
p ≤ 0.01). 
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Figure 13. LUCAT1 regulates the stability of DNMT1. KYSE-30 cells were treated 
with siLUCAT1s, siCT, and HA-ubiquitin transfection and MG132 (10 μM). Cell 
lysates were immunoprecipitated with DNMT1 antibody to detect the 
polyubiquitination of DNMT1 using Ub antibody (a). Flag-UHRF1 or siUHRF were 
transfected and detected with Ub antibody in the same manner (b). 
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Figure 14. LUCAT1 regulates the expression of tumor suppressor genes through 
regulation of DNMT1. LUCAT1 increases the stability of DNMT1 and inhibits the 
expression of tumor suppressor genes. (a) When the expression of LUCAT1 is inhibited, 
the ubiquitination of DNMT1 is induced and the gene expression of tumor suppressor 
genes is activated (b). 
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Ⅳ. DISCUSSION 
Long non-coding RNAs (lncRNAs) have been shown to have various roles and 
functions in terms of physiological and pathological aspects, and reports have shown 
that most non-coding RNAs have biological functions by regulating gene expression. 
In particular, the dysregulation of lncRNAs plays an important role in cancer formation 
and is closely associated with the development and progression of gastric, colon, lung, 
and other types of cancer. Thus, it has emerged as a biomarker for cancer diagnosis and 
many reports have been published.
4,21-23
 Despite the many reports indicating that 
lncRNAs are associated with cancer, few studies have identified the specific 
mechanism. 
Recently, the discovery and analysis of non-coding RNAs have been enhanced by 
RNA-seq technology, and different pipelines have been developed to identify novel 
lncRNAs using RNA-seq data.
5,24,25
 However, despite successful studies highlighting 
the important roles of lncRNAs in different tissues and diseases,
12,13,15,18  
little is 
known about the roles of lncRNAs in ESCC. Furthermore, the biological inference of 
lncRNA functions remains a challenging task, given their currently limited annotation 
status and low expression levels. 
In this study, we focused on LUCAT1, which was highly overexpressed in ESCC 
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cancer tissues according to RNA-seq data. LUCAT1 was significantly related with the 
proliferation and invasion of ESCC. The survival rate of ESCC was determined by the 
expression of LCUAT1. We found that LUCAT1 regulates the expression of DNMT1 in 
a UHRF1 (an epigenetic regulator of DNMT1)-dependent manner. The mechanism of 
action of LUCAT1 we have found is in good agreement with the recent finding that 
lncRNA is directly involved in DNA methylation. In particular, LUCAT1 directly 
regulated UHRF1, which acted as a key epigenetic regulator by bridging DNA 
methylation and chromatin modification in this study. This has not been shown in prior 
research and is thus a very interesting finding. 
DNA methylation is one of the fundamental epigenetic mechanisms to regulate gene 
transcription, which involves the addition of a methyl group to cytosines that are 
typically restricted to CpG dinucleotides.
26
 Epigenetic changes caused by DNA 
methylation are important for the onset and progression of cancer.
7
 In particular, the 
promoter methylation of the tumor suppressor gene results in transcriptional silencing 
and loss of gene function and subsequently drives cancer development.
8
 We first 
focused on the tumor suppressor genes whose expression is upregulated after siRNA 
LUCAT1 in a microarray and subsequent qRT-PCR and whose major regulation is 
DNA methylation. SiLUCAT1 reduced the methylation of GADD45G, GAS1, SFRP2, 
and HPGD, which are known cancer tumor suppressors,
27-30
 and upregulated the 
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expression of these proteins. Among them, GADD45G and SFRP2 have been reported 
to be methylated in ESCC, and their expression has been reported to be related to 
cancer formation as a tumor suppressor.
31,32
 We confirmed that LUCAT1 is involved in 
the methylation of a series of tumor suppressor genes, and this finding was not related 
with histone modification.  
 In our study, siLUCAT1 reduced the level of DNMT1 protein in the KYSE-30 cell 
line but not mRNA. DNMT1 knockdown was reported to induce apoptosis, inhibit the 
proliferation of ESCC, and lead to the demethylation of tumor suppressor genes.
33
 We 
found that LUCAT1 expression was closely related with the polyubiquitination of 
DNMT1 in KYSE-30 through experiments on the knockdown and ectopic expression 
of LUCAT1. UHRF1 was reported as the major component to induce proteasomal 
degradation targeting DNMT1 by acetylation caused by acetyltransferase Tip60.
34
 The 
overexpression of UHRF1 was reported to increase the ubiquitination of DNMT1.
20,34
 
We found that the knockdown of UHRF1 absolutely blocked the DNMT1 
ubiquitination induced by the siRNAs of LUCAT1. In our study, the 
stability/ubiquitination of DNMT1 was regulated by LUCAT1 in a UHRF1-dependent 
manner. Recently, lncRNA UPAT (ubiquitin-like plant homeodomain (PHD) and really 
interesting new gene (RING) finger domain-containing protein 1 (UHRF1) Protein 
Associated Transcript) was reported to promote colon carcinogenesis by inhibiting the 
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degradation of UHRF1.
35
 
To date, whether the stability of genes is regulated by lncRNAs remains unexplored. 
Several reports have indicated the role of lncRNA in the regulation of gene stability. 
Anti-differentiation ncRNA (ANCR) has been shown to modulate EZH2 stability, and it 
has been found to be a novel potential tumor suppressor in breast cancer through 
modulating the EMT process and cell migration.
36
 Our study added one more lncRNA, 
LUCAT1, which can control DNMT1 stability by controlling ubiquitination. 
LUCAT1, reported as an lncRNA SCAL1 induced by tobacco smoke in smokers’ 
airways and upregulated in many lung cancer cell lines, is bound to and regulated by 
NRF2.
17
 In our study, LUCAT1 showed a relationship with NRF2 in the ESCC cell line 
(data not shown), but this association was not a major pathway for the development of 
ESCC. Therefore, we had to find a new mechanism of LUCAT1’s involvement in 
ESCC development in this study. 
LUCAT1 was significantly upregulated in ESCC tissues compared to adjacent normal 
tissue of patients with ESCC, and the aberrant expression of LUCAT1 was associated 
with ESCC prognosis. These findings suggest that LUCAT1 is an onset and prognostic 
marker of ESCC. One interesting finding in this study is that LUCAT1 expression in 
adjacent normal tissues of patients with ESCC was significantly greater than in normal 
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esophageal tissues. This result suggests that LUCAT1 can be used as a predictor for the 
development of ESCC and that early control of LUCAT1 can even prevent the 
development of ESCC.  
In our study, we found that LUCAT1 activated DNMT1, a major DNA methylation 
pathway, to repress the expression of tumor suppressor genes, leading to ESCC (Fig. 
14). Since LUCAT1 is expected to play a major role as a predictive marker for ESCC 
and a target for preventive drugs.  
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Ⅴ. CONCLUSION 
LUCAT1 was significantly upregulated in ESCC tissues compared with that in 
adjacent normal tissue of patients with ESCC. Aberrant expression of LUCAT1 was 
associated with prognosis of ESCC. Thus, LUCAT1 may be an effective marker of the 
onset and prognosis of ESCC.  
Collectively, Our results thus suggest that LUCAT1 regulates the stability of 
DNMT1 and inhibits the expression of tumor suppressors through DNA methylation, 
leading to the invasion and proliferation of ESCC. We identified LUCAT1 as a 
potential target for drug development and as a biomarker for ESCC. 
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ABSTRACT (IN KOREAN) 
 
Long non coding RNA LUCAT1의  
DNMT1 ubiquitination 조절을 통한 
식도편평상피암의 발암기전 
 
<지도교수 이 상 길> 
 
연세대학교 대학원 의과학과 
 
윤 정 호 
 
식도편평상피암 (ESCC)은 예후가 좋지 않은 치명적인 악성 종양으로 암발
생과 전이 기전이 잘 알려져 있지 않다. 최근에 많은 long non-coding RNA 
(lncRNA)가 다양한 암 발생과 전이에 관여하는 것으로 보고 되었다. 이번 
연구에서는 ESCC에서 LUCAT1의 기전을 검증하였다. 13명 식도편평상피암 
환자의 암 조직과 주변 정상조직의 RNA를 사용하여 RNA-seq deep 
sequencing을 진행하였다. lncRNA 중 LUCAT1은 주변 정상 조직과 비교하였
을때 ESCC에서 확연하게 과발현되어 있음을 확인하였다 (p <0.001). 
LUCAT1은 ESCC 세포주 및 ESCC 환자의 암 조직에서 각각 정상 세포 및 주
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변 정상 조직과 비교하였을때 확연하게 과발현되어 있는 것을 확인하였다 
(p <0.001). ESCC 환자의 암에 주변 정상 조직에서 LUCAT1의 발현은 정상 
환자의 조직과 비교하여도 확연하게 높았다(p <0.001). KYSE-30 세포주와 
HCE-4 세포주에서 LUCAT1의 발현은 apoptosis를 차단하고 KYSE-30 세포주
와 HCE-4 세포주의 이동과 침습을 유도하였다. siRNA를 이용한 LUCAT1의 
발현억제는 이러한 유전자의 메틸화를 줄임으로써 GADD45G, GAS1, HPGD 및 
SFRP2를 비롯한 종양 억제 유전자들의 발현을 증가시켰다. LUCAT1의 발현
억제는 전사의 간섭 없이 DNA 메틸 전이 효소 1 (DNMT1)의 단백질 수준을 
감소 시켰다. LUCAT1은 E3 ubiquitin-protein ligase UHRF1에 의존적인 방
식으로 DNMT1의 ubiquitination과 분해를 조절했다. LUCAT1의 발현이 높은 
환자는 LUCAT1의 발현이 낮은 환자보다 생존율이 현저히 낮았다. 결론적으
로 본 연구의 결과는 lncRNA LUCAT1이 DNMT1의 안정성을 조절하고 ESCC의 
형성과 전이로 이어지는 DNA 메틸화를 통해 종양 억제 인자의 발현을 억제 
함을 시사한다. 이번 연구에서는 ESCC에 대한 약물 및 바이오 마커의 표적
으로 LUCAT1의 가능성을 발견했다. 
 
 
 
 
 
핵심되는말: long non-coding RNA, LUCAT1, DNA 메틸 전이 효소 1,  
식도 편평 상피 암 
